Paclitaxel Protein Bound Particles for Injectable Suspension (Albumin Bound) (Lyophilized):
Medication Type: Paclitaxel protein-bound particles are administered via injection.
Purpose: This formulation is used to treat various cancers, including breast, lung, and pancreatic cancer.
Composition: It consists of paclitaxel, a chemotherapy medication, bound to albumin, a protein found in blood.
Mechanism of Action: Paclitaxel disrupts the function of cancer cells by inhibiting their ability to divide and grow, while the albumin helps to deliver the medication to the tumor site.
Dosage: The dosage and frequency of administration are determined by a healthcare provider based on factors such as the type and stage of cancer, as well as the patient's overall health.
Administration: Administered intravenously after reconstitution with a compatible diluent.
Side Effects: Common side effects may include hair loss, nausea, vomiting, fatigue, and decreased blood cell counts.
Precautions: Patients should be monitored closely for signs of allergic reactions and bone marrow suppression during treatment.
Interactions: Paclitaxel may interact with other medications, so it's important to inform the healthcare provider about all medications being taken.
Quadruple CPD-SAGM Blood Bag system (350 ml), primary bag containing ,anticoagulant CPD solution I.P. 49 ml for collection & preservation of 350 ml .Human blood & one bag contains additive SAGM solution 78 ml.
STERILE NON-TOXIC NON-PYROGENIC
Each 100ml of Anticoagulant Citrate Phosphate Dextrose (CPD) Solution I.P. contains:
Quadruple CPD-SAGM Blood Bag system (350 ml), primary bag containing , anticoagulant CPD solution I.P. 49 ml for collection & preservation of 350 ml . Human blood & one bag contains additive SAGM solution 78 mlSTERILE NON-TOXIC NON-PYROGENICEach 100ml of Anticoagulant Citrate Phosphate Dextrose (CPD) Solution I.P. contains:
Treosulfan for Injection 5 gm/vial is a sterile lyophilized powder used for intravenous administration. It contains 5 grams of Treosulfan, an alkylating agent commonly used in combination with other chemotherapeutic drugs as part of a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT). Treosulfan exerts its anti-cancer effects by inducing DNA cross-linking, which interferes with DNA replication and cell division, ultimately leading to cell death. It has both myeloablative and immunosuppressive properties, making it suitable for patients undergoing transplantation, especially those with hematologic malignancies.
Key Features:
Active Ingredient: Treosulfan – 5 gm
Form: Lyophilized powder for injection
Administration: Intravenous use after reconstitution
Indication: Pre-conditioning treatment in HSCT
Packaging: Single-use glass vial in a protective carton
